Alcohol Addiction – Pipeline Review, H1 2019 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Alcohol Addiction – Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering. This latest Pharmaceutical…
Pharmaceuticals, Biotechnology and Life Sciences
DUBLIN–(BUSINESS WIRE)–The “Alcohol Addiction – Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering. This latest Pharmaceutical…
DUBLIN–(BUSINESS WIRE)–The “Diabetes Therapies Global Market Opportunities And Strategies To 2023” report has been added to ResearchAndMarkets.com’s offering. This report…
BOSTON–(BUSINESS WIRE)–Cerveau Technologies, Inc. today announced a research collaboration agreement with Eisai Inc., which will enable Eisai to use Cerveau’s…
Eisai Co said Friday thata global Phase III clinical study (Clarity AD/Study 301) of BAN2401, an anti-amyloid beta protofibril antibody, in patients with early Alzheimer’s disease has been initiated.
Neurotrope said Friday, commenting Biogen Inc.’s decision to discontinue its global Phase 3 trials of aducanunab in Alzheimer’s disease, Phase 2 clinical trial using its drug Bryostatin during the second half of 2019.
ProMIS Neurosciencesissued a pres release Friday, raising urgency to selectively target the toxic oligomer with exacting precision as part of the global effort to develop disease-modifying therapies for Alzheimer’s disease (AD), upon Biogen’s and Eisai’s dropping two alte-stage clinical trials of aducanumab.
INNOVATE-3 will test the efficacy of Tumor Treating Fields combined with paclitaxel in patients with recurrent, platinum-resistant ovarian cancer ST.…
Application supported by the Phase 3 MAIA study for daratumumab in combination with lenalidomide and dexamethasone for the treatment of…
ALAMEDA, Calif.–(BUSINESS WIRE)–AgeX Therapeutics, Inc. (“AgeX”, NYSE American: AGE), a biotechnology company focused on innovative therapeutics for human aging, announced…
DUBLIN–(BUSINESS WIRE)–The “Whole Slide Imaging Market – Growth, Trends, and Forecast (2019 – 2024)” report has been added to ResearchAndMarkets.com’s…